Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03157089
Title Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (LUX-Lung IO)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Boehringer Ingelheim

lung squamous cell carcinoma


Afatinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | FRA | ESP

No variant requirements are available.